Assessment of Bronchodilator Response in Patients with CF and Non-CF Bronchiectasis-A Randomized Controlled Study

Area of Science:

• Pulmonology
• Respiratory Medicine
• Clinical Trials

Background:

• Bronchiectasis often presents with nonreversible obstructive lung function.
• Some bronchiectasis patients exhibit bronchodilator response (BDR), leading to bronchodilator use.
• Assessing BDR in cystic fibrosis (CF) and other bronchiectatic diseases requires further investigation.

Purpose of the Study:

• To assess bronchodilator response (BDR) in patients with cystic fibrosis (CF), primary ciliary dyskinesia (PCD), and non-CF/PCD bronchiectasis.
• To compare BDR between these patient groups and healthy controls (HCs).
• To evaluate BDR using different calculation methods in a randomized controlled setting.

Main Methods:

• A randomized controlled study involving 69 patients (CF, PCD, non-CF/PCD) and 20 HCs.
• Participants received either salbutamol followed by placebo, or placebo followed by salbutamol.
• BDR was calculated using American Thoracic Society (ATS)/European Respiratory Society (ERS) standards (new and old methods).

Main Results:

• Patients with CF and PCD demonstrated a statistically significant greater mean response to salbutamol compared to placebo.
• Significant BDR (new method, >10%) was rare: 0 in CF, 2 in PCD, 0 in non-CF/PCD, and 2 in HCs.
• The old method identified BDR in an additional PCD patient and three non-CF/PCD patients.

Conclusions:

• Clinically significant bronchodilator response (BDR) appears uncommon in patients with bronchiectasis.
• While CF and PCD patients showed a greater response to salbutamol than placebo, its clinical significance is unclear.
• Further research is needed to determine the therapeutic implications and optimal methods for assessing BDR in bronchiectasis.